Worldwide Clinical Trials
Company Overview
Worldwide Clinical Trials is a globally recognized Contract Research Organization (CRO) with over 30 years of experience in delivering full-service clinical trials and drug development services across 60+ countries. The company specializes in early and late-stage drug development across various therapeutic areas, including Cardiovascular & Metabolic, Oncology, Neuroscience, and Cell & Gene Therapy. Worldwide Clinical Trials is distinguished by its personalized client engagement and commitment to high-quality clinical trial capabilities.
Key Services and Expertise
The organization offers a comprehensive suite of clinical services, including Phase I-IV clinical trials, real-world evidence, pharmacovigilance, bioanalytical lab assessments, transition studies, and patient recruitment. Their consulting capabilities encompass protocol development, quality assurance, and trial optimization.
Leadership Team
- Peter Benton, MBA - President and Chief Executive Officer: Leads with vast expertise in operational, commercial, financial, and technical domains.
- Sherilyn Adcock, RPh, PhD - Chief Scientific Officer, Early Phase Development: Drives early-phase clinical insights and solutions.
- David Bowser, MBA - Executive Vice President and Chief Operating Officer: Enhances operational agility and strategic partnerships.
- Angelico Carta, MD - President and Co-Founder: Focused on global sales and corporate growth.
- Joy Clark - Chief People Officer: Cultivates organizational culture and talent acquisition.
- Sara Davis - Executive Vice President and Chief Commercial Officer: Manages commercial strategies and sales initiatives.
- Peter Lammers - Executive Vice President of Marketing and Commercial Operations: Oversees global marketing operations.
- Kellie MacLeod - Executive Vice President, Global Quality Assurance: Ensures quality compliance in clinical operations.
- Jason Meggs - Chief Financial Officer: Manages financial and legal strategies.
- Mike Mencer - Executive Vice President and General Manager, Early Phase: Directs early-phase drug development projects.
- Michael Murphy, MD, PhD - Chief Medical and Scientific Officer: Leads medical and scientific strategic planning.
- Henry J. Riordan, PhD - Chief Development Officer: Advances neuroscience development programs.
Recent Developments
Worldwide Clinical Trials secured a recapitalization with Kohlberg & Company, enhancing its financial capacity for growth and strategic direction in the CRO market.
Historical Context
Founded by Dr. Neal R. Cutler in 1986, Worldwide Clinical Trials transitioned from an investigational site to a full-fledged CRO by 1995. Noted for its emphasis on site and patient-centered research, the company excels particularly in central nervous system disorders. The organization reports an annual estimated revenue of $535.3 million and employs 3889 staff members, reflecting a 15% growth in the workforce over the past year.
Competitor Landscape
Worldwide Clinical Trials competes with multiple CROs, including PRA Health Sciences, Syneos Health, Cambridge Cognition Holdings, Fortrea US, and RTI Health Solutions. RTI Health Solutions, for instance, is recognized for its extensive research and consulting services.
Strategic Insights
The organization stands out through its rigorous methodological approaches and commitment to quality. Its recognition in the 2024 Industry Standard Research Phase II/III Benchmarking Report attests to its excellence in performance, focusing on speed, quality, and safety in drug development.
Additional Information
Worldwide Clinical Trials' strong management oversight and innovative sales enablement technologies facilitate successful project execution. The company's strategic focus on client-centric and quality-driven approaches ensures its competitive edge in the dynamic CRO industry landscape.
